Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs e l f Beauty Inc (ELF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs e l f Beauty Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while e l f Beauty Inc trades at $76.93 (market cap $4.52B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 8.8× e l f Beauty Inc's market cap, and e l f Beauty Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | ELF | |
|---|---|---|
Market Cap | $39.89B | $4.52B |
Sector | Health | Technology |
52-Week High | $491.22 | $146.67 |
52-Week Low | $278.09 | $49.57 |
Enterprise Value | $38.15B | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
ELF trades at $76.75, up 1.31% with bullish technical signals and strong earnings beats. The stock shows robust revenue growth and high gross margins, though valuation multiples appear elevated. Recent news highlights brand expansion and market share gains, with analyst sentiment mixed but leaning positive.
Outlook remains optimistic due to consistent earnings outperformance and strategic initiatives, but risks include high P/E ratio, competitive pressures, and sensitivity to tariffs. Upside potential exists if growth targets are met, yet investors should weigh valuation concerns against growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About e l f Beauty Inc
e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →
